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To determine the effectiveness and safety of once-daily
combination therapy with amlodipine, valsartan and
hydrochlorothiazide for reducing ambulatory blood
pressure (ABP) in patients with moderate to severe
hypertension, a multicenter, double-blind study was
performed (N¼2271) that included ABP monitoring in a
283-patient subset. After a single-blind, placebo run-in
period, patients were randomized to receive amlodipine/
valsartan/hydrochlorothiazide (10/320/25mg), valsartan/
hydrochlorothiazide (320/25mg), amlodipine/valsartan
(10/320mg) or amlodipine/hydrochlorothiazide (10/25mg)
each morning for 8 weeks. Efficacy assessments included
change from baseline in 24-h, daytime and night time
mean ambulatory systolic BP (SBP) and diastolic BP
(DBP). Statistically significant and clinically relevant
reductions from baseline in all these parameters occurred
in all treatment groups (Po0.0001, all comparisons
versus baseline). At week 8, least squares mean reduc-
tions from baseline in 24-h, daytime and night time
mean ambulatory SBP/DBP were 30.3/19.7, 31.2/20.5 and
28.0/17.8mmHg, respectively, with amlodipine/valsartan/
hydrochlorothiazide; corresponding reductions with dual
therapies ranged from 18.8–24.1/11.7–15.5, 19.0–25.1/
12.0–16.0 and 18.3–22.6/11.1–14.3mmHg (Pp0.01, all
comparisons of triple versus dual therapy). Treatment
with amlodipine/valsartan/hydrochlorothiazide maintained
full 24-h effectiveness, including during the morning
hours; all hourly mean ambulatory SBP and mean
ambulatory DBP measurements were p130/85mmHg
at end point. Amlodipine/valsartan/hydrochlorothiazide
combination therapy was well tolerated. Once-daily
treatment with amlodipine/valsartan/hydrochlorothia-
zide (10/320/25mg) reduces ABP to a significantly
greater extent than component-based dual therapy and
maintains its effectiveness over the entire 24-h dosing
period.
Journal of Human Hypertension (2011) 25, 615–622;
doi:10.1038/jhh.2010.115; published online 20 January 2011
Keywords: triple therapy; amlodipine; valsartan; hydrochlorothiazide
Introduction
The blood pressure (BP) surge that occurs between
6 AM and noon
1 has been associated with a peak in
the incidence of cardiovascular events and sudden
death.
2 This surge in BP (B10–30mmHg in systolic
BP (SBP) and 7–23mmHg in diastolic BP (DBP))
2
coincides with an increase in pulse rate and
sympathetic tone and activation of the renin-
angiotensin-aldosterone system.
3–6 In turn, activa-
tion of the renin-angiotensin-aldosterone system
results in increased levels of aldosterone and
angiotensin II, a potent vasoconstrictor that mod-
ulates vasomotor tone, cell growth and extracellular
matrix deposition.
7 Several studies have shown that
among patients who appear to have well-controlled
morning BP, as assessed by office measurements,
B60% have poorly controlled morning BP when
assessed by ambulatory BP monitoring (ABPM).
8,9
It is well established that the majority of patients
with hypertension require two or more antihyper-
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www.nature.com/jhhtensive agents from complementary classes to
achieve BP control,
10–13 and the results from several
recent studies indicate that B23–54% of patients
with hypertension require three or more agents.
10,14–17
Results were recently reported for the first large-scale,
randomized, double-blind clinical trial designed
to compare the effectiveness and safety of once-
daily triple therapy with the calcium channel
blocker amlodipine (Aml), the angiotensin receptor
antagonist valsartan (Val) and the thiazide diuretic
hydrochlorothiazide (HCTZ) (10/320/25mg) versus
component-based dual therapy with Val/HCTZ,
Aml/Val or Aml/HCTZ for the treatment of moderate
to severe hypertension.
18 The results of this study
showed that triple therapy with Aml/Val/HCTZ was
well tolerated and was significantly more effective
in reducing mean sitting SBP (MSSBP) and mean
sitting DBP (MSDBP) and in providing BP control
than component-based dual therapy. The current
article reports the results of ABPM in a subgroup of
patients who participated in this triple-therapy
study. The objective was to determine the effective-
ness of triple therapy for controlling BP throughout
the 24-h interval.
Methods
This study was a randomized, double-blind, paral-
lel-group, active-control trial conducted in 15
countries. The study design, patient selection
criteria and disposition of all patients enrolled were
reported in detail by Calhoun et al.
18
Study treatment
The study included an antihypertensive washout
period and single-blind, placebo run-in period of up
to 4 weeks, followed by an 8-week, double-blind
treatment period (Figure 1). At the end of the placebo
run-in period, patients were randomly assigned
(1:1:1:1) to receive triple therapy with Aml/Val/HCTZ
(10/320/25mg) or dual therapy with Val/HCTZ
(320/25mg), Aml/Val (10/320mg) or Aml/HCTZ
(10/25mg). Randomization was achieved using a
validated, interactive, voice-response system. As
shown in Figure 1, the study design included a
two-step dose-escalation period in the triple-therapy
arm and a single-step dose-escalation period in each
of the dual-therapy arms over the first 2 weeks,
followed by 6 weeks of treatment at full dosage
administered once-daily at 8 AM. On study visit
days, patients were instructed not to take their study
medication until assessments were completed.
Patients
Patients 18–85 years of age with moderate or severe
hypertension (grade 2 or 3 or stage 2;
19,20 MSSBP
X145 and o200mmHg and MSDBP X100 and
o120mmHg) were eligible to participate. Patients
were excluded if, at screening, they were receiving
four or more antihypertensive agents; three anti-
hypertensive agents and had an MSSBP/MSDBP
X140/90mmHg; two antihypertensive agents and
had an MSSBP/MSDBP X180/110mmHg; or no
antihypertensive agents and had an MSSBP/MSDBP
o140/90mmHg. Other key exclusion criteria
Figure 1 Study design.
18 Aml, amlodipine; HCTZ, hydrochlorothiazide; Val, valsartan.
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renal disease and concomitant type 1 diabetes or
uncontrolled type 2 diabetes, as previously de-
scribed.
18
Patients meeting the screening criteria were immedi-
ately randomly assigned to receive treatment if MSSBP
was X180mmHg or MSDBP was X110mmHg. The
remaining patients were randomly assigned to re-
ceive treatment after a placebo run-in period of up to
4 weeks if MSSBP was X145mmHg and MSDBP was
X100mmHg. Patients were removed from the study
if they experienced MSSBP X200mmHg or MSDBP
X120mmHg at any time during the study.
Efficacy assessments
The MSSBP and MSDBP measurements were
obtained at each study visit, as reported by Calhoun
et al.
18 Per protocol, 24-h ABPM was conducted at
baseline before randomization (week 1) and after 8
weeks of double-blind treatment (week 9) in a subset
of patients enrolled in the study. Patients were fitted
on the non-dominant arm with a Spacelabs 90207
ABPM device (Spacelabs Healthcare Supplies, Issa-
quah, WA, USA) between 0700 hours and 1000 hours
on the first day of each monitoring period, and the
device was calibrated to within ±7mmHg against
the mean of three DBP readings.
21 Pressure cuffs
were set to inflate every 20min over a 24-h time
period and to deflate at a rate of 8mmHg per 2
heartbeats. The ABPM device was removed on the
second or third day of each period after a minimum
of 24h, and the ABPM data were downloaded and
evaluated on site using study-specific ABPM soft-
ware (Medifacts International, Rockville, MD, USA).
If the ABPM data did not meet pre-specified quality
control criteria, the entire ABPM procedure could be
repeated at the discretion of the study investigator.
Statistical analyses
The primary efficacy variables were change from
baseline in MSSBP and MSDBP at week 9, as
described by Calhoun et al.
18 Secondary end points
reported herein included the change from baseline
in 24-h, daytime (0600 hours to 2200 hours) and
night time (2200 hours to 0600 hours) mean
ambulatory SBP (MASBP) and mean ambulatory
DBP (MADBP). Mean 24-h ABPM data from the
intent-to-treat population were analyzed using an
analysis of covariance model for repeated measures
with treatment, region and postdosing hour as
factors, baseline 24-h mean ABPM results as a
covariate, and treatment by postdosing-hour inter-
actions. Daytime and night time ABPM data from
the intent-to-treat population were analyzed using
an analysis of covariance model for repeated measures
with treatment, region and time (daytime, night time)
as factors, baseline 24-h mean ABPM results as a
covariate, and treatment-by-time interactions. The
mean changes from baseline in MASBP and MADBP
(with 95% confidence intervals) were assessed at
week 9. The differences in the mean changes from
b a s e l i n ei nM A S B Pa n dM A D BP between the triple-
therapy arm and the dual-therapy arms were esti-
mated using least squares mean data. MASBP and
MADBP at each hour were summarized at baseline
and end point for each treatment group.
Further, post hoc analyses of morning (0600 hours
to 2400 hours) MASBP and MADBP were individu-
ally performed using an analysis of covariance
model with treatment and region as factors and
baseline 24-h mean ABPM results as a covariate.
Multiplicity adjustment for P-values from the
analyses of primary efficacy variables was described
by Calhoun et al.
18 No multiplicity adjustment was
made for P-values from the analyses of ABPM data.
Additionally, post hoc summary statistics were
performed to assess the mean reductions in 24-h
ambulatory BP (ABP) in patients grouped according
to the severity of hypertension at baseline as as-
sessed by clinic SBP (X140 and o160mmHg; X160
and o200mmHg; X180 and o200mmHg).
Results
Baseline characteristics of the patients undergoing ABPM
Of the 4285 patients enrolled, 2271 were assigned to
double-blind treatment and 2060 (90.7%) completed
treatment,
18 including all 283 patients who under-
went 24-h ABPM. The demographic and baseline
characteristics of the subgroup of patients under-
going ABPM were similar between treatment arms
(Table 1), and similar to those of the study popula-
tion as a whole.
18 Of the patients undergoing ABPM,
baseline MSSBP/MSDBP was 165.2/105.2mmHg
and MASBP/MADBP was 148.2/93.4mmHg.
Changes from baseline in MASBP and MADBP
All four treatments resulted in clinically relevant
and statistically significant reductions from baseline
in least squares MASBP and MADBP over the 24-h
dosing period and during the daytime and night
time hours (Figure 2; Po0.0001 versus baseline for
all comparisons). However, the improvements in
24-h, daytime and night time ABP were greatest in
patients receiving Aml/Val/HCTZ (Pp0.01 for all
comparisons). Among the patients receiving triple
therapy, the 24-h MASBP decreased by 30.3mmHg
(95% confidence interval:  31.7,  28.8) and the
24-h MADBP decreased by 19.7mmHg (95% con-
fidence interval:  20.7,  18.7). Consistent results
were observed for the daytime and night time hours.
The absolute 24-h, daytime and night time
MASBP/MADBP levels at study end point were
lowest in the triple-therapy group (119/75, 123/78
and 111/68mmHg, respectively).
Hourly ABP over the 24-h dosing period
Mean hourly ABPM data obtained at baseline and
at week 9 are presented in Figure 3. At baseline,
24-hour blood pressure control with triple therapy
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were 480mmHg at all time points throughout the 24-h
dosing period in all treatment groups. At the end of the
study (week 9), all (100%) of the hourly MASBP levels
were p130mmHg in the Aml/Val/HCTZ group. In
comparison, 91.7, 83.3 and 41.7% of the hourly
MASBP levels were o130mmHg in the Val/HCTZ,
Aml/Val and Aml/HCTZ groups, respectively. All
hourly end point MADBP levels were o85mmHg in
the triple-therapy group and 87.5% (21 of 24) of the
hourly levels were o80mmHg.
Changes from baseline in early morning MASBP and
MADBP
Statistically significant greater reductions from base-
line in morning MASBP and MADBP were observed
in patients receiving triple therapy (30.2/20.6mmHg)
compared with Val/HCTZ (24.5/15.7mmHg; Po0.01),
Val/Aml (24.6/15.4 mm Hg; Po0.01) and HCTZ/Aml
(19.7/12.4mmHg; Po0.0001). MASBP/MADBP be-
tween 0600 hours and 1200 hours was 124/
80mmHg in the triple-therapy group.
24-h ABP by severity of hypertension at baseline
Reductions in 24-h MASBP were greater across all
treatment groups in the subgroups of patients with
baseline MSSBP X160 and o200mmHg or baseline
MSSBP X180 and o200mmHg, compared with the
reductions in patients with baseline MSSBP X140 and
o160mmHg (Figure 4). In patients with baseline
MSSBP X160 and o200mmHg or and patients with
baseline MSSBP X180 and o200mmHg, decreases in
MASBP were greater with Aml/Val/HCTZ (34.2 and
37.0mmHg, respectively) than with dual therapy
(range: 21.0–26.4 and 22.5–31.2mmHg, respectively).
Similarly, decreases in MASBP in patients with base-
line MSSBP X140 and o160mmHg were also greater
with triple therapy than with dual therapy.
Discussion
This is the first large-scale, controlled trial to
prospectively study the effects of once-daily triple
therapy with Aml/Val/HCTZ versus component-
based dual therapy for controlling ABP throughout














Male 42 (55.3) 40 (56.3) 40 (58.0) 42 (62.7)
Age, mean (s.d.), years 55.5 (8.9) 53.6 (9.3) 53.0 (8.5) 54.1 (9.9)
Age group, n (%)
X65 years 16 (21.1) 9 (12.7) 5 (7.2) 10 (14.9)
Race, n (%)
White 60 (78.9) 54 (76.1) 56 (81.2) 54 (80.6)
Black 14 (18.4) 12 (16.9) 10 (14.5) 10 (14.9)
Other 2 (2.6) 5 (7.0) 3 (4.4) 3 (4.5)
Ethnicity, n (%)
Hispanic/Latino 13 (17.1) 8 (11.3) 13 (18.8) 9 (13.4)
Non-Hispanic/Latino 63 (82.9) 63 (88.7) 56 (81.2) 58 (86.6)
BMI, mean (s.d.), kgm
 2 30.9 (4.7) 30.8 (4.7) 32.0 (5.6) 31.2 (5.2)
Sitting BP, mean (s.d.), mmHg
SBP 164.6 (13.5) 166.3 (13.5) 164.4 (12.2) 165.6 (13.3)
DBP 105.5 (4.4) 105.0 (4.4) 104.9 (5.0) 105.4 (3.9)
24-h ambulatory BP, mean (s.d.), mmHg
SBP 147.3 (13.1) 149.7 (14.2) 146.4 (13.5) 149.6 (13.4)
DBP 93.4 (9.4) 93.1 (8.1) 92.8 (9.1) 94.4 (10.0)
Severity of baseline systolic HTN, n (%)
MSSBP X140 and o160mmHg 33 (43.4) 26 (36.6) 26 (37.7) 31 (46.3)
MSSBP X160 and o200mmHg 43 (56.6) 45 (63.4) 43 (62.3) 36 (53.7)
MSSBP X180 and o200mmHg 12 (15.8) 15 (12.1) 7 (10.1) 11 (16.4)
Baseline SBP, mean (s.d.), mmHg
MSSBP X140 and o160mmHg 153.1 (4.1) 152.9 (4.5) 151.6 (4.2) 154.1 (4.4)
MSSBP X160 and o200mmHg 173.4 (11.4) 174.1 (10.4) 172.1 (8.3) 175.5 (9.9)
MSSBP X180 and o200mmHg 189.2 (6.3) 186.9 (6.3) 185.4 (5.1) 187.5 (5.1)
Abbreviations: Aml, amlodipine; BMI, body mass index; BP, blood pressure; DBP, diastolic BP; HCTZ, hydrochlorothiazide; HTN, hypertension;
MSSBP, mean sitting SBP; SBP, systolic BP; s.d., standard deviation; Val, valsartan.
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subgroup of patients corroborate the clinic BP
findings from the entire study population.
18 Overall,
the ABPM data show that treatment with Aml/Val/
HCTZ lowered MASBP/MADBP by B30/20mmHg
throughout the 24-h period, which was significantly
better than the reductions achieved in patients
receiving dual therapy. An even greater improve-
ment in MASBP (reductions of 37mmHg) was
observed among triple-therapy patients with severe
systolic hypertension at baseline (MSSBP X180 and
o200mmHg).
The results from the current study further show
that the reductions in ABP are relatively uniform
throughout the 24-h dosing period. Notably, at end
point, hourly MASBP/MADBP levels among pa-
tients receiving Aml/Val/HCTZ remained p130/
85mmHg for every hour of the 24-h dosing period,
including the early morning hours. MASBP/MADBP
between 0600 hours and 1200 hours, the hours
coinciding with the morning surge in BP, was 124/
80mmHg in the triple-therapy group. The ABP
levels achieved with triple therapy are clinically
relevant considering the 24-h, daytime and night
time means were lower than the lower end of
the European Society of Hypertension/European
Society of Cardiology SBP/DBP target goal ranges
for ABP (125–130/80, 130–135/85 and 120/70
mmHg, respectively).
20
The results from this ABPM subgroup analysis, in
conjunction with the results from the primary
efficacy analysis,
18 have important implications for
the management of patients with moderate to severe
hypertension. The consistent reductions in ABP
observed in this study throughout the 24-h dosing
Figure 2 Least squares mean change from baseline in 24-h,
daytime and night time ambulatory (a) SBP and (b) DBP.
Hexagons represent baseline values and circles represent end
point values. Dotted lines indicate the upper end of the European
Society of Hypertension/European Society of Cardiology target
ranges for MASBP/MADBP (24h: 125–130/80mmHg; daytime:
130–135/85mmHg; night time: 120/70mmHg).
20 *Pp0.0001
versus Aml/Val/HCTZ; **Pp0.001 versus Aml/Val/HCTZ;
***Pp0.01 versus Aml/Val/HCTZ. Aml, amlodipine; ESH/ESC,
European Society of Hypertension/European Society of Cardio-
logy; HCTZ, hydrochlorothiazide; MADBP, mean ambulatory
diastolic blood pressure; MASBP, mean ambulatory systolic blood
pressure; Val, valsartan.
Figure 3 Hourly MASBP (a) and MADBP (b) at baseline and end
point over the 24-h dosing interval. Dotted lines indicate the
upper end of the European Society of Hypertension/European
Society of Cardiology target range for mean 24-h MASBP/MADBP
(125–130/80mmHg).
20 Aml, amlodipine; ESH/ESC, European
Society of Hypertension/European Society of Cardiology; HCTZ,
hydrochlorothiazide; MADBP, mean ambulatory diastolic blood
pressure; MASBP, mean ambulatory systolic blood pressure; Val,
valsartan.
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to be a strong predictor of cardiovascular morbidity
and mortality.
22,23 Moreover, ABPM over 24h is the
most accurate method of assessing the effectiveness
of antihypertensive therapy
24 and can characterize
BP during the early morning hours, when cardio-
vascular and cerebrovascular events are most likely
to occur.
2 At the same time, however, there is a lack
of evidence that controlling the morning BP surge
translates into a reduction in cardiovascular
events.
25 Nonetheless, attaining 24-h BP control is
a goal of antihypertensive therapy. In this regard,
several studies (including the recently completed
effects of force-titrated valsartan/hydrochlorothia-
zide versus amlodipine/hydrochlorothiazide on
ambulatory blood pressure in patients with stage 2
hypertension (EVALUATE) study
26) have shown
that dual therapy with angiotensin receptor blockers
in combination with a non-renin-angiotensin-aldos-
terone system antihypertensive agent is effective
for controlling ABP throughout the day, including
the high-risk hours coinciding with the morning
surge in BP.
27–32 The results from this study
show that additional improvements in ABP can be
achieved throughout the day, including the morning
hours, with angiotensin receptor blocker-based triple
therapy that incorporates agents with complemen-
tary mechanisms of action.
Our study excluded individuals who were on four
or more antihypertensive agents. This exclusion
may have led to a greater percentage of patients
responding to triple therapy as well as dual therapy
in our study. However, for ethical reasons, it was not
considered appropriate to enroll patients who were
in need of four or more antihypertensive agents
because the trial only allowed for a maximum of
three drugs per patient. As with all clinical trials,
study entry criteria can limit extrapolation of results
to a broader patient population.
Conclusion
In patients with moderate to severe hypertension,
once-daily therapy with Aml/Val/HCTZ (10/320/
25mg) reduces ABP throughout the 24-h dosing
interval, including the overall 24-h, daytime and
night time periods, to a significantly greater extent
than component-based dual therapy. Aml/Val/HCTZ
lowers MASBP/MADBP by B30/20mmHg through-
out the day in these patients with even greater
reduction observed in those patients with more
severe systolic hypertension. Notably, triple therapy
with Aml/Val/HCTZ effectively controls MASBP to
p130mmHg for every hour throughout the day,
including early morning hours.
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Figure 4 Change from baseline in 24-h MASBP according to the
severity of hypertension at baseline. Hexagons represent baseline
values and circles represent end point values. Dotted line
indicates the upper end of the European Society of Hyperten-
sion/European Society of Cardiology target range for mean 24-h
MASBP (125–130mmHg).
20 Aml, amlodipine; ESH/ESC, Eur-
opean Society of Hypertension/European Society of Cardiology;
HCTZ, hydrochlorothiazide; MASBP, mean ambulatory systolic
blood pressure; MSSBP, mean sitting systolic blood pressure; Val,
valsartan.
What is known about this topic
K 24-h BP control is an important component of an effective
antihypertensive treatment regimen.
K The morning surge in BP is associated with a peak in the
incidence of cardiovascular complications, yet evidence
linking control of this surge to improved cardiovascular
outcomes is lacking.
K BP control remains an issue, despite current
antihypertensive therapeutic options, and up to half of
patients treated for hypertension have uncontrolled BP.
A number of combination antihypertensive agents are
available that have shown benefits.
What this study adds
K In patients with moderate to severe hypertension, once-
daily triple combination therapy (amlodipine/valsartan/
hydrochlorothiazide) resulted in statistically significant
and clinically relevant reductions from baseline in 24-h,
daytime and nighttime MASBP and MADBP versus
baseline.
K Ambulatory BP assessments also showed greater reductions
with triple therapy compared with component dual-
combination therapy.
K Triple-combination therapy effectively controlled MASBP
to p130mmHg for every hour throughout the day,
including early morning hours when most cardiovascular
complications are likely to occur.
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